CCRM
Rajvee Shah is an experienced operations associate currently working at CCRM since November 2021, previously holding the position of Operations Associate I. Prior experience includes serving as a Biological Activity Technologist at Labstat International Inc. from May 2020 to November 2021, where work took place in a GLP compliant and ISO17025 accredited laboratory, focusing on mammalian cell lines. Prior roles also include a Pizza Maker at Domino's from October 2018 to February 2020 and a Research Associate at 3B Biotech Biologics Development Centre, where significant contributions were made to increase Virginiamycin production and manage multiple projects. Rajvee Shah holds a Master's degree in Medical Biotechnology from the University of Windsor and a Master of Science in Microbiology from The Maharaja Sayajirao University of Baroda, along with a Bachelor's degree in Microbiology from Natubhai V. Patel College of Pure and Applied Sciences.
CCRM
1 followers
Regenerative Medicine (RM), which aims to harness the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs, has the promise to treat, manage and perhaps cure some of the most devastating and costly diseases in the world today. Many new and potentially life-changing RM-based treatments never reach patients because they are not successfully moved from the laboratory to a stage where they can be used in medicine. In order to fulfill RM’s promise to treat the many diseases affecting our population, a world-renowned group of stem cell scientists and engineers have come together to form CCRM, a leader in developing and commercializing regenerative medicine and cell therapy technologies. CCRM formally launched on June 14, 2011. CCRM supports the development and commercialization of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy.